Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)
ID: 344128Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $300K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/344128

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-007.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering the Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders, aimed at supporting early-stage investigators in transformative research related to substance use disorders and addiction. This grant program encourages innovative proposals in the fields of chemistry and pharmacology, providing funding of up to $300,000 per year for a maximum of five years, with an overall annual commitment of $3 million. The program is particularly significant as it fosters groundbreaking research that addresses public health challenges associated with substance use disorders, while clinical trials are not permitted under this funding opportunity. Interested applicants must submit their letters of intent and applications by the specified deadlines, with the closing date for applications set for August 7, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DA-24-007-Full-Announcement.html
    RFA-DA-24-007.html
    The Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders, administered by the National Institute on Drug Abuse (NIDA), aims to support early-stage investigators conducting transformative research in substance use disorders and addiction. This program seeks innovative proposals in chemistry and pharmacology, providing funding of up to $300,000 per year for five years, with an overall commitment of $3 million annually. The application cycle opens on July 9, 2023, with key deadlines for letters of intent and applications. Eligible applicants include higher education institutions, non-profits, and foreign entities, while clinical trials are not permitted under this funding opportunity. The review process focuses on the scientific merit of the proposals, emphasizing significance, innovation, and the investigator's potential for creative research. An important aspect of the application includes a detailed essay outlining the project's significance and innovativeness. This award is designed for new investigators lacking preliminary data for traditional grants like the R01, thus fostering future leaders in the field. Overall, the Avenir Award promotes groundbreaking research in addressing substance use disorders through novel chemical and pharmacological methodologies, aiming to significantly impact public health and addiction treatment strategies.
    Similar Opportunities
    Avenir Award Program for Research on Substance Use Disorders and HIV (DP2 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Avenir Award Program for Research on Substance Use Disorders and HIV, aimed at supporting early-stage investigators conducting innovative research at the intersection of HIV and substance use. This grant program encourages studies that align with NIH HIV/AIDS research priorities, focusing on reducing HIV transmission, optimizing therapies for co-occurring conditions, and enhancing treatment strategies for affected populations. Eligible applicants include a diverse range of institutions such as higher education institutions, non-profits, and government agencies, with a budget cap of $375,000 annually for up to four years, totaling $1.5 million in direct costs. Interested parties can find more information and application details at the provided NIH link, with the application deadline set for August 15, 2025.
    Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Avenir Award Program for early-stage investigators focused on the genetics or epigenetics of substance use disorders (SUDs). This grant program aims to support innovative research that has the potential to significantly advance the understanding of addiction, particularly for those researchers who may lack preliminary data typically required for larger grants. The funding opportunity, which totals up to $300,000 annually for a maximum of five years, encourages applications from a diverse range of eligible institutions, including historically underrepresented groups. Interested applicants can submit their proposals until September 25, 2025, and should refer to the full announcement for detailed submission guidelines and requirements, available at NIH Grants. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Substance Use/Substance Use Disorder Dissertation Research Award (R36), aimed at supporting doctoral candidates for up to two years in their dissertation research related to substance use disorders. This grant, under the National Institute on Drug Abuse (NIDA), encourages applications from diverse backgrounds and focuses on advancing knowledge in prevention, diagnosis, and treatment of substance misuse and related health outcomes, excluding independent clinical trials. Eligible applicants can receive up to $50,000 per year for innovative research aligned with NIDA’s strategic plan, with applications due by September 7, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDA Avant-Garde Program for HIV and Substance Use Disorder Research, a federal grant opportunity aimed at supporting innovative research proposals that address the intersection of HIV/AIDS and substance use disorders. This program seeks to fund exceptionally creative scientists who can propose high-impact studies that diverge significantly from existing research paths, with a focus on transformative approaches to prevention and treatment. The grant provides funding of up to $700,000 annually for a maximum duration of five years, with a submission deadline of August 14, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDA Avant-Garde Program for HIV and Substance Use Disorder Research, aimed at supporting innovative research that intersects HIV and substance use disorders. This grant opportunity encourages creative scientists to propose high-impact studies that lead to new therapies and preventative strategies for HIV among drug users, emphasizing originality and alignment with NIH’s HIV/AIDS research priorities. The program allows for clinical trial proposals with a funding ceiling of $700,000 per year for up to five years, with applications due by August 15, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the "Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)" to support doctoral candidates in completing their dissertation research projects related to substance use disorders. This funding initiative aims to enhance the pool of talented researchers in the field by providing grants of up to $50,000 per year for direct costs over a maximum of two years, with a focus on projects that align with the National Institute on Drug Abuse (NIDA) strategic priorities. Applications are particularly encouraged from individuals who can contribute to diversifying the research workforce, and interested candidates must submit their applications by October 16, 2023, or on February 16 and June 16, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications that support a diverse range of preclinical and clinical projects, with the goal of advancing medication studies toward FDA approval, emphasizing the importance of innovative approaches to drug misuse and addiction treatment. Eligible applicants include a variety of institutions, such as higher education entities and community organizations, with funding available up to $5 million per year for projects lasting up to three years. Interested parties can find more information and submit inquiries via grantsinfo@nih.gov, with applications due by August 11, 2025.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity for the development of medications aimed at preventing and treating substance use disorders (SUDs) and overdose. This initiative is structured into two phases: the UG3 phase focuses on achieving specific milestones within a two-year period, while the UH3 phase extends support for an additional three years for projects that successfully meet the UG3 milestones. Given the urgent need for effective treatments in light of rising overdose deaths, particularly from synthetic opioids and stimulants, this funding opportunity emphasizes innovative research methodologies and the effective application of existing medications. Interested applicants can seek funding of up to $3 million annually for a maximum of five years, with applications due by August 11, 2025. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-329.html.
    Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity aimed at the development of medications to prevent and treat opioid and stimulant use disorders and overdose. This initiative seeks innovative preclinical and clinical research projects that can lead to FDA-approved therapies, focusing on areas such as prevention of substance use initiation, treatment adherence, and reduction of overdose risks. With a maximum funding amount of $3 million per year over a project period of five years, applicants are encouraged to submit proposals that demonstrate their capability to manage the research effectively, adhering to detailed application instructions. Interested parties can find more information and application details at the NIH grants website, with the application deadline set for September 1, 2025.